The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers.
When propafenone is given with digoxin, digoxin serum concentrations increase. Although the digoxin-propafenone interaction is well known clinically, the mechanism by which propafenone interferes with digoxin elimination is unclear. To test the hypothesis that propafenone or one or both of its two major metabolites, 5-hydroxypropafenone (5-OHP) and N-depropylpropafenone (NDPP), inhibit the P-glycoprotein-mediated net renal tubular secretion of digoxin, we examined the transport of digoxin and the well-studied P-glycoprotein substrate vinblastine across confluent Madin-Darby canine kidney cell monolayers in the absence and presence of propafenone, 5-OHP and NDPP. Propafenone and its two major metabolites significantly inhibit the secretory flux of digoxin and vinblastine (propafenone > 5-OHP >> NDPP). Despite decreases in net transport, cellular digoxin accumulation did not decrease, suggesting that neither propafenone nor its metabolites prohibited digoxin from entering the cells at the basolateral side. NDPP, but not 5-OHP, was detected after 48 hr of incubation of the cells with propafenone alone. When the cells were incubated with propafenone or 5-OHP, apical accumulation of 5-OHP, but neither propafenone nor NDPP, against a concentration gradient was observed. These findings are consistent with the hypothesis that the digoxin-propafenone interaction results from the inhibition of the renal tubular transport of digoxin by propafenone and its metabolites. Our data suggest that propafenone is an inhibitor of P-glycoprotein, whereas 5-OHP is a possible substrate.
Woodland
C
C
Division of Clinical Pharmacology and Toxicology, The Research Institute, The Hospital for Sick Children, The University of Toronto, Ontario, Canada.
Verjee
Z
Z
Giesbrecht
E
E
Koren
G
G
Ito
S
S
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000502:physiology; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D002478:Cells, Cultured; D004077:Digoxin / Q000493:pharmacokinetics*; D004285:Dogs; D004347:Drug Interactions; D005260:Female; D007684:Kidney Tubules / Q000166:cytology / Q000378:metabolism*; D011405:Propafenone / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology*; D014747:Vinblastine / Q000493:pharmacokinetics
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000889:Anti-Arrhythmia Agents; D014747:Vinblastine; D011405:Propafenone; D004077:Digoxin; C044307:5-hydroxypropafenone; C045806:N-depropylpropafenone